In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Biotronik trial milestones

This article was originally published in The Gray Sheet

Executive Summary

Biotronik enrolls the first patient July 23 in its 1,750-patient REPLACE registry, the first and largest prospective trial focusing on complications associated with replacements and system upgrades of FDA-approved implantable pacemakers and defibrillators. The registry will be conducted in 75 to 100 U.S. centers and will include all manufacturers' models. Also on July 23, Biotronik completed enrollment in its 1,000-patient TRUST study. The randomized, prospective trial is evaluating if patients with Lumos and Lumax VT-T/DR-T defibrillators followed by Biotronik's Home Monitoring and IEGM Online remote monitoring technology have outcomes at least equivalent to those receiving standard in-person follow up...

You may also be interested in...



COVID-19: WHO Supports Pooling Of Rights, MPP Includes Drugs and Tests

Intellectual property rights are in the spotlight again, after the World Health Organization and the Medicines Patent Pool announced initiatives to help ensure that all countries will be able to access products being developed for COVID-19.

'Hunker Down, Expect The Worst And Hope For The Best:' Investment Analyst Advises Medtech Businesses To Cut Costs

Maxim Jacobs, managing director at Edison Investment Research urges medtech companies to be financially prudent as the COVID-19 pandemic worsens. Cancellations of routine surgeries are creating a huge strain on device companies which could continue for months.

COVID-19: WHO Supports Pooling Of Rights, MPP Includes Drugs and Tests

Intellectual property rights are in the spotlight again, after the World Health Organization and the Medicines Patent Pool announced initiatives to help ensure that all countries will be able to access products being developed for COVID-19.

UsernamePublicRestriction

Register

MT025062

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel